Author | Roy S. Herbst, MD, PhD

Articles

Expert on Emergence of Osimertinib, New Discoveries in Lung Cancer Care

June 15, 2020

Roy S. Herbst, MD, PhD, presented a late breaking abstract on behalf of his colleagues regarding the ADAURA trial, which analyzed osimertinib as an adjuvant therapy to treat patients with non-small cell lung cancer.

Roy S. Herbst, MD, PhD, Discusses ADAURA Trial and Future of Lung Cancer Treatment

June 12, 2020

Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed the future of lung cancer treatment to follow the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.

Roy S. Herbst, MD, PhD, Talks Key Takeaway from Phase III ADAURA Trial

June 03, 2020

Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.

Immunotherapy in Lung Cancer

August 26, 2015

In this interview with Dr. Roy S. Herbst, we discuss the FDA approval of nivolumab for lung cancer as well as other immunotherapies under investigation for the treatment of lung cancer.